Amgen Inc (AMGN)

Etorro trading 970x250

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; and Eli Lilly and Company. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Amgen Inc News and around…

Latest news about Amgen Inc (AMGN) common stock and company :

2 Best Biotech Stocks to Buy Right Now
18 Oct, 2021 FinancialContent

These dividend stocks provide sustainable and growing dividends, which are nearly triple the S&P 500's yield.

Crispr: A Fallen Angel In Gene Editing
16 Oct, 2021 FinancialContent

As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it becomes profitable, investors will come flocking back.

We Did The Math IUSG Can Go To $118
14 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Core S&P US.

How to Find Stocks on Sale in 2021
14 Oct, 2021 FinancialContent

Despite the major stock indexes trading not far off their highs, some stocks have sold off and are now trading near their 52-week lows. Could there be some deals among those that are being discarded by Wall Street?

Got $5,000? 3 Top Dividend Stocks to Buy Right Now
13 Oct, 2021 FinancialContent

These companies can deliver regular income -- to live off of in retirement or to buy more stock with.

Jasper Therapeutics Stock Soars after Oppenheimer Calls it a Buy
13 Oct, 2021 Yahoo! Finance

By Sam Boughedda

Noteworthy Tuesday Option Activity: IBM, AMGN, TJX
12 Oct, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in International Business Machines Corp (IBM), where a total volume of 21,297 contracts has been traded thus far today, a contract volume which is representative of approximately 2.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.3% of IBM's average daily trading volume over the past month, of 4.4 million shares..

Expert Ratings For Amgen
12 Oct, 2021 FinancialContent

Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Blade Therapeutics Mourns the Passing of General Counsel and Secretary Alan C. Mendelson
11 Oct, 2021 FinancialContent

Blade Therapeutics mourns the passing of General Counsel and Secretary Alan C. Mendelson

Amgen (AMGN) Reports New Data From Lumakras Combo Study
08 Oct, 2021 Yahoo! Finance

Amgen (AMGN) reports new combination data from the phase Ib CodeBreaK 101 study. It also buys a stake in Neumora Therapeutics to advance novel therapies for brain diseases.

3 High-Yielding Dividend Stocks Trading Near Their 52-Week Lows
08 Oct, 2021 FinancialContent

They may not be growth machines, but these stocks can generate a whole lot of dividend income for you.

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

10 Best Big Pharma Stocks to Buy Now
08 Oct, 2021 Yahoo! Finance

In this article, we discuss the 10 best big pharma stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Big Pharma Stocks to Buy Now. On September 9, the United States Department of Health and Human Services (HHS) unveiled a comprehensive plan to reduce drug […]

Debt Ceiling Agreement Helps Benchmarks Win 3 Straight
07 Oct, 2021 FinancialContent

Better-than-expected jobless claims data for the week also boosted sentiment, with reopening and tech stocks leading the charge.

Amgen Highlights Lumakras Combination Data From Solid Tumor Trials
07 Oct, 2021 FinancialContent

Amgen Inc(NASDAQ: AMGN)announced new combination study resultsfrom the Phase 1b CodeBreaK 101 study of Lumakras ...

With $500M and Amgen deal, startup emerges to target brain diseases
07 Oct, 2021 Yahoo! Finance

"The challenge with neuroscience is you can't biopsy the brain," said the data chief of this startup. "But you can biopsy data."

Amgen Announces New LUMAKRAS™ (sotorasib) Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers At AACR-NCI-EORTC 2021
07 Oct, 2021 Yahoo! Finance

Amgen (NASDAQ: AMGN) today announced new combination study results from the Phase 1b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™ (sotorasib), the first and only approved KRASG12C inhibitor, in more than 10 different investigational combination regimens for the treatment of patients with KRAS G12C-mutated cancers. Results from two arms of the study — LUMAKRAS with afatinib, a pan-ErbB tyrosine kinase inhibitor, and LUMAKRAS wit

3 Dividend-Paying Nasdaq 100 Stocks to Buy Hand Over Fist in October
07 Oct, 2021 FinancialContent

These three Nasdaq 100 stocks provide market-beating yields and steady growth potential at attractive valuations.

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Amgen, Neumora Collaborate On Precision Therapies for Brain Diseases
07 Oct, 2021 FinancialContent

Amgen Inc(NASDAQ: AMGN) andNeumora Therapeutics Inchave announced a strategic collaboration to advance neuroscience ...

Amgen to invest $100 million in SoftBank-backed Neumora
07 Oct, 2021 Yahoo! Finance

U.S. biotech Amgen Inc has made a $100-million equity investment in Neumora Therapeutics, the brain disease drug developer said on Thursday, adding that it will also get global rights to develop and sell certain of Amgen's experimental drugs for neurodegenerative diseases. Neumora said Amgen's investment, along with $400 million it had raised from other investors including SoftBank Vision Fund, will help it bring precision medicines – already used in the field of cancer treatments – for complex brain diseases.

Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases
07 Oct, 2021 Yahoo! Finance

Amgen (NASDAQ: AMGN) and Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company pioneering precision medicines for brain diseases, announced a strategic collaboration to advance neuroscience discovery, development and commercialization. The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities. In addition, Neumora has received a $100

Psychiatric drug startup launches with $500M, Amgen partnership
07 Oct, 2021 Yahoo! Finance

For the last two years, Neumora Therapeutics Inc. has been operating in stealth mode, quietly amassing a treasure trove of venture capital. Now that it's well past the point of scientific validation, Neumora is ready to make its public debut.

How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?
06 Oct, 2021 Yahoo! Finance

Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data.

11 Dividend Contenders For Growth And Income
06 Oct, 2021 FinancialContent

Despite the general high valuation of the overall market, these research candidates are currently sound and attractive.

This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
05 Oct, 2021 Yahoo! Finance

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment
04 Oct, 2021 Yahoo! Finance

Amgen (NASDAQ:AMGN) today announced results from real-world data in Asia, Europe, Oceania, and North and South America on the temporal trends in hip fracture incidence, and in post-fracture pharmacological treatment intervention. The study, presented as a late-breaking abstract at the American Society for Bone and Mineral Research 2021 Annual Meeting (ASBMR), is titled "Hip Fractures: Initial Report of Trends in Incidence, Treatment, and Mortality In Multiple Countries Using a Common Analytical

Should I Buy Amgen, Inc. (AMGN)?
04 Oct, 2021 Yahoo! Finance

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks initially suffered […]

2 Ridiculously Cheap Growth Stocks to Buy
02 Oct, 2021 FinancialContent

Though these companies have recorded solid financials of late, investors are overlooking them.

Amgen Inc (AMGN) is a NASDAQ Common Stock listed in , ,

970x250